Table 4.
Univariate analysis for progression free survival and overall survival for patients with non-small-cell lung cancer treated immune checkpoint inhibitor monotherapy
| Factor | PFS | OS | ||||
|---|---|---|---|---|---|---|
| Survival at 1 year, % (95% CI) | HR (95% CI) | p | Survival at 1 year, % (95% CI) | HR (95% CI) | p | |
| Age group | ||||||
| < 75 years (n = 189) | 27.2 (20.8–34.0) | 1 | 0.47 | 52.9 (44.9–60.2) | 1 | 0.89 |
| ≥ 75 years (n = 74) | 28.8 (16.1–42.7) | 1.13 (0.81–1.59) | 51.1 (35.8–64.5) | 1.03 (0.70–1.51) | ||
| Sex | ||||||
| Female (n = 82) | 26.6 (17.0–37.2) | 1 | 0.21 | 45.4 (33.6–56.4) | 1 | 0.063 |
| Male (n = 181) | 28.3 (21.2–35.7) | 0.82 (0.61–1.11) | 56.1 (47.3–64.0) | 0.72 (0.51–1.02) | ||
| Smoking status | ||||||
| Brinkman index ≥ 400 (n = 199) | 29.6 (22.7–36.8) | 1 | 0.005* | 55.7 (47,4–63.2) | 1 | 0.032* |
| Brinkman index < 400 (n = 64) | 21.7 (12.3–32.8) | 1.59 (1.15–2.17) | 44.1 (30.8–56.6) | 1.49 (1.03–2.16) | ||
| ECOG-PS | ||||||
| 0/1 (n = 183) | 34.8 (27.4–42.4) | 1 | < 0.001* | 61.1 (52.6–68.5) | 1 | < 0.001* |
| ≥ 2 (n = 80) | 12.3 (5.7–21.5) | 1.92 (1.43–2.56) | 33.3 (22.0–45.1) | 2.65 (1.89–3.73) | ||
| Histological subtype | ||||||
| Squamous (n = 64) | 25.8 (15.2–37.7) | 1 | 0.88 | 57.6 (41.9–70.5) | 1 | 0.55 |
| Non-squamous (n = 199) | 28.5 (21.7–35.6) | 0.97 (0.70–1.35) | 51.1 (43.2–58.5) | 1.13 (0.76–1.68) | ||
| Number of organs involved | ||||||
| 0 or 1 (n = 101) | 41.9 (31.0–52.4) | 1 | < 0.001* | 73.1 (61.3–81.7) | 1 | < 0.001* |
| ≥ 2 (n = 162) | 19.4 (13.3–26.3) | 1.89 (1.39–2.56) | 41.0 (32.5–49.2) | 2.19 (1.51–3.18) | ||
| Presence of brain metastasis | ||||||
| No (n = 197) | 26.8 (20.1–33.9) | 1 | 0.34 | 54.6 (46.2–62.3) | 1 | 0.28 |
| Yes n = 66) | 30.6 (19.7–42.1) | 1.17 (0.85–1.62) | 47.2 (34.2–59.1) | 1.22 (0.85–1.76) | ||
| Presence of bone metastasis | ||||||
| No (n = 177) | 33.7 (26.1–41.5) | 1 | < 0.001* | 64.9 (56.1–72.3) | 1 | < 0.001* |
| Yes (n = 86) | 15.8 (8.6–24.9) | 1.87 (1.40–2.51) | 29.3 (19.3–40.0) | 2.84 (2.02–3.99) | ||
| Presence of liver metastasis | ||||||
| No (n = 211) | 31.3 (24.5–38.3) | 1 | < 0.001* | 57.1 (49.0–64.3) | 1 | 0.0021* |
| Yes (n = 52) | 14.6 (6.5–25.7) | 1.79 (1.29–2.49) | 36.3 (23.2–49.7) | 1.80 (1.24–2.61) | ||
| PD-L1 expression | ||||||
| ≥ 50% (n = 79) | 42.4 (30.1–54.1) | 1 | 0.0014* | 60.7 (47.4–71.6) | 1 | 0.28 |
| < 50% or unknown (n = 184) | 21.6 (15.5–28.3) | 1.73 (1.24–2.42) | 49.3 (40.9–57.1) | 1.24 (0.84–1.83) | ||
| EGFR mutation status | ||||||
| Negative or unknown (n = 236) | 31.1 (24.7–37.6) | 1 | < 0.001* | 57.0 (49.5–63.8) | 1 | < 0.001* |
| Positive (n = 27) | NA | 3.99 (2.59–6.14) | 19.2 (7.0–36.0) | 2.64 (1.70–4.10) | ||
| Initially chosen ICI | ||||||
| Atezolizumab (n = 43) | 18.2 (5.0–37.9) | 1 | 0.0034* | 19.6 (4.0–44.0) | 1 | 0.044* |
| Nivolumab (n = 140) | 23.7 (16.9–31.2) | 0.78 (0.52–1.19) | 50.8 (41.8–59.1) | 0.69 (0.42–1.16) | ||
| Pembrolizumab (n = 80) | 41.3 (28.7–53.4) | 0.47 (0.30–0.77) | 65.8 (51.9–76.6) | 0.48 (0.27–0.86) | ||
| Previous lines of chemotherapy | ||||||
| 0 (n = 58) | 39.8 (24.0–55.1) | 1 | 0.015* | 74.0 (58.6–84.4) | 1 | 0.071 |
| ≥ 1 (n = 205) | 24.3 (18.3–30.8) | 1.63 (1.10–2.41) | 48.4 40.7–55.7) | 1.59 (0.96–2.62) | ||
| GRIm score | ||||||
| Low (0/1) (n = 166) | 34.4 (26.6–42.4) | 1 | < 0.001* | 62.1 (53.2–69.7) | 1 | < 0.001* |
| High (2/3) (n = 87) | 17.1 (9.6–26.6) | 1.89 (1.41–2.55) | 37.8 (26.2–49.3) | 2.31 (1.63–3.28) | ||
| Maximum diameter of target lesions | ||||||
| Max BTS ≤ 50 mm (n = 135) | 37.4 (28.6–46.3) | 1 | < 0.001* | 62.3 (52.3–70.7) | 1 | < 0.001* |
| Max BTS > 50 mm (n = 128) | 17.6 (11.0–25.5) | 1.92 (1.44–2.57) | 42.5 (32.8–52.0) | 2.24 (1.59–3.14) | ||
PFS progression free survival, OS overall survival, NSCLC non-small-cell lung cancer, ICI immune checkpoint inhibitor, HR hazard ratio, CI confidence interval, ECOG-PS eastern cooperative oncology group-performance status, PD-L1 programmed death-ligand 1, EGFR epidermal growth factor receptor, GRIm score Gustave Roussy Immune Score, BTS baseline tumor size